BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12800575)

  • 1. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 2. Investing in oncology biotech stocks.
    Feuerstein A
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):879-80. PubMed ID: 18185485
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech bonanza.
    Stipp D
    Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
    [No Abstract]   [Full Text] [Related]  

  • 4. Nasdaq restructures biotech index.
    Morrison C
    Nat Biotechnol; 2001 Mar; 19(3):187. PubMed ID: 11231518
    [No Abstract]   [Full Text] [Related]  

  • 5. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 6. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 7. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 8. Can personalized drugs pay off?
    Stipp D
    Fortune; 2002 May; 145(10):168. PubMed ID: 12025349
    [No Abstract]   [Full Text] [Related]  

  • 9. Public biotech 98: the numbers.
    Lähteenmäki R; Michael A; Marshall A
    Nat Biotechnol; 1999 May; 17(5):429-32. PubMed ID: 10331795
    [No Abstract]   [Full Text] [Related]  

  • 10. When a long shot is worth a shot.
    Jacobs T; Fischer J
    Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
    [No Abstract]   [Full Text] [Related]  

  • 11. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

  • 12. A special biotech speculation.
    Jacobs T
    Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
    [No Abstract]   [Full Text] [Related]  

  • 13. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 14. Eli Lilly enters venture capital arena.
    Fletcher L
    Nat Biotechnol; 2001 Nov; 19(11):997-8. PubMed ID: 11689830
    [No Abstract]   [Full Text] [Related]  

  • 15. No pain, no gain?
    Jacobs T
    Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
    [No Abstract]   [Full Text] [Related]  

  • 16. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 17. Finding new life in health stocks.
    Armour LA
    Fortune; 1997 Sep; 136(6):289-90, 292, 294. PubMed ID: 10173398
    [No Abstract]   [Full Text] [Related]  

  • 18. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 19. IPO floodgates unlikely to open after Ark floatation.
    Louët S
    Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538
    [No Abstract]   [Full Text] [Related]  

  • 20. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.